The under-representation of older people in clinical trials: barriers and potential solutions

D W Habicht1, M D Witham, M E T McMurdo

  • 1Section of Aging and Health, Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK. dhabicht@nhs.net

Insights

Older adults are under-represented in clinical trials, leading to poor evidence for healthcare decisions. Addressing trial exclusion of frail older people is crucial for equitable health equity and high-quality care.

Area of Science:

  • Gerontology
  • Clinical Trial Methodology
  • Health Equity

Background:

  • Frail older adults are a core demographic for health services but remain under-represented in clinical research.
  • The limited evidence base for this population hinders effective clinical decision-making.
  • Exclusion from trials creates an inequitable healthcare landscape for older individuals.

Purpose of the Study:

  • To investigate the reasons behind the exclusion of frail older people from clinical trials.
  • To propose actionable solutions to enhance the inclusion of this demographic in research.
  • To advocate for equitable standards of healthcare and research participation for older adults.

Main Methods:

  • Literature review on clinical trial demographics and exclusion criteria.
  • Analysis of barriers to older adult participation in clinical research.
  • Synthesis of existing strategies and recommendations for improving inclusion.

Main Results:

  • Identified significant under-representation of frail older adults in numerous clinical trials.
  • Highlighted systemic and practical barriers contributing to exclusion.
  • Noted some progress but emphasized the need for continued efforts.

Conclusions:

  • The under-representation of frail older adults in clinical trials persists, impacting evidence-based practice.
  • Addressing exclusion requires multifaceted solutions targeting trial design, recruitment, and ethical considerations.
  • Ensuring equitable participation is essential for advancing geriatric healthcare and research.

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...